Review Article
Hypertension in the Elderly
Table 1
main clinical trials on hypertensive patients.
| | Acronym | Patients | Age | Drugs |
| | ACTION | 7.665 | 63.5* | Nifedipine GITS | | ALLHAT | 40.000 | ≥55 years | Chortalidone, amlodipine, lisinopril, doxazosin, pravastatin | | ELITE | 722 | ≥65 | Losartan, captopril | | HOT | 18.790 | 50–80 | Felodipine, hydroclorotiazide, atenolol, ACEI | | INSIGH | 6.321 | 55–80 | Nifedipine, amiloride | | SYST-EUR | 4.227 | 60–79 | Nitrendipine, enalapril, hydroclorotiazide | | ANBP2 | 6.000 | 65–84 | Enalapril versus ββ/αβ/diuretic/antiCa++ | | CAPP | 7.000 | 25–66 | Captopril versus ββ/diuretics | | LIFE | 9.193 | 55–85 | Losartan versus atenolol | | NORDIL | 10.881 | 50–69 | Diltiazem versus ββ/diuretic | | PROGRESS | 6.000 | 64* | Perindopril. Indapamide | | CONVINCE | 16.602 | >55 | Verapamil** versus/atenolol/hydroclorotiazide | | VALUE | 14.400 | >50 | Valsartan, amlodipine | | HYVET | 2.100 | >80 | Indapamide, perindopril |
|
|
*Median Age; **Verapamil Slow Release.
|
